Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 94


Regression of Stage IV Pancreatic Cancer to Curative Surgery and Introduction of a Novel Ex-Vivo Chemosensitivity Assay.

Rios Perez MV, Dai B, Koay EJ, Wolff RA, Fleming JB.

Cureus. 2015 Dec 21;7(12):e423. doi: 10.7759/cureus.423.


Neoadjuvant FOLFIRINOX for borderline resectable pancreas cancer: a new treatment paradigm?

Christians KK, Tsai S, Mahmoud A, Ritch P, Thomas JP, Wiebe L, Kelly T, Erickson B, Wang H, Evans DB, George B.

Oncologist. 2014 Mar;19(3):266-74. doi: 10.1634/theoncologist.2013-0273. Epub 2014 Feb 25.


Paclitaxel as Albumin-Bound Nanoparticles with Gemcitabine for Untreated Metastatic Pancreatic Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.

Stainthorpe A, Greenhalgh J, Bagust A, Richardson M, Boland A, Beale S, Duarte R, Kotas E, Banks L, Palmer D.

Pharmacoeconomics. 2018 Oct;36(10):1153-1163. doi: 10.1007/s40273-018-0646-1. Review.


Attenuated FOLFIRINOX in the salvage treatment of gemcitabine-refractory advanced pancreatic cancer: a phase II study.

Kim JH, Lee SC, Oh SY, Song SY, Lee N, Nam EM, Lee S, Hwang IG, Lee HR, Lee KT, Bae SB, Kim HJ, Jang JS, Lim DH, Lee HW, Kang SY, Kang JH.

Cancer Commun (Lond). 2018 Jun 4;38(1):32. doi: 10.1186/s40880-018-0304-1.


Safety and tolerability of the first-in-class agent CPI-613 in combination with modified FOLFIRINOX in patients with metastatic pancreatic cancer: a single-centre, open-label, dose-escalation, phase 1 trial.

Alistar A, Morris BB, Desnoyer R, Klepin HD, Hosseinzadeh K, Clark C, Cameron A, Leyendecker J, D'Agostino R Jr, Topaloglu U, Boteju LW, Boteju AR, Shorr R, Zachar Z, Bingham PM, Ahmed T, Crane S, Shah R, Migliano JJ, Pardee TS, Miller L, Hawkins G, Jin G, Zhang W, Pasche B.

Lancet Oncol. 2017 Jun;18(6):770-778. doi: 10.1016/S1470-2045(17)30314-5. Epub 2017 May 8.


FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.

Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de la Fouchardière C, Bennouna J, Bachet JB, Khemissa-Akouz F, Péré-Vergé D, Delbaldo C, Assenat E, Chauffert B, Michel P, Montoto-Grillot C, Ducreux M; Groupe Tumeurs Digestives of Unicancer; PRODIGE Intergroup.

N Engl J Med. 2011 May 12;364(19):1817-25. doi: 10.1056/NEJMoa1011923.


Metastasized pancreatic carcinoma with neoadjuvant FOLFIRINOX therapy and R0 resection.

Schneitler S, Kröpil P, Riemer J, Antoch G, Knoefel WT, Häussinger D, Graf D.

World J Gastroenterol. 2015 May 28;21(20):6384-90. doi: 10.3748/wjg.v21.i20.6384.


Is there a role for surgical resection in patients with pancreatic cancer with liver metastases responding to chemotherapy?

Crippa S, Bittoni A, Sebastiani E, Partelli S, Zanon S, Lanese A, Andrikou K, Muffatti F, Balzano G, Reni M, Cascinu S, Falconi M.

Eur J Surg Oncol. 2016 Oct;42(10):1533-9. doi: 10.1016/j.ejso.2016.06.398. Epub 2016 Jun 29.


Advancements in the management of pancreatic cancer: 2013.

Saif MW.

JOP. 2013 Mar 10;14(2):112-8. doi: 10.6092/1590-8577/1481.


Cost-effectiveness of systemic therapies for metastatic pancreatic cancer.

Tam VC, Ko YJ, Mittmann N, Cheung MC, Kumar K, Hassan S, Chan KK.

Curr Oncol. 2013 Apr;20(2):e90-e106. doi: 10.3747/co.20.1223.


Is the therapeutic index better with gemcitabine-based chemoradiation than with 5-fluorouracil-based chemoradiation in locally advanced pancreatic cancer?

Crane CH, Abbruzzese JL, Evans DB, Wolff RA, Ballo MT, Delclos M, Milas L, Mason K, Charnsangavej C, Pisters PW, Lee JE, Lenzi R, Vauthey JN, Wong AB, Phan T, Nguyen Q, Janjan NA.

Int J Radiat Oncol Biol Phys. 2002 Apr 1;52(5):1293-302.


Effect of adjuvant capecitabine or fluorouracil, with or without oxaliplatin, on survival outcomes in stage III colon cancer and the effect of oxaliplatin on post-relapse survival: a pooled analysis of individual patient data from four randomised controlled trials.

Schmoll HJ, Twelves C, Sun W, O'Connell MJ, Cartwright T, McKenna E, Saif M, Lee S, Yothers G, Haller D.

Lancet Oncol. 2014 Dec;15(13):1481-92. doi: 10.1016/S1470-2045(14)70486-3. Epub 2014 Nov 12.


FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis.

Suker M, Beumer BR, Sadot E, Marthey L, Faris JE, Mellon EA, El-Rayes BF, Wang-Gillam A, Lacy J, Hosein PJ, Moorcraft SY, Conroy T, Hohla F, Allen P, Taieb J, Hong TS, Shridhar R, Chau I, van Eijck CH, Koerkamp BG.

Lancet Oncol. 2016 Jun;17(6):801-810. doi: 10.1016/S1470-2045(16)00172-8. Epub 2016 May 6. Review.


Efficacy of different chemotherapy regimens in treatment of advanced or metastatic pancreatic cancer: A network meta-analysis.

Zhang SH, Liu GF, Li XF, Liu L, Yu SN.

J Cell Physiol. 2018 Apr;233(4):3352-3374. doi: 10.1002/jcp.26183. Epub 2017 Nov 1.


Gemcitabine versus FOLFIRINOX in patients with advanced pancreatic adenocarcinoma hENT1-positive: everything was not too bad back when everything seemed worse.

Orlandi A, Calegari MA, Martini M, Cocomazzi A, Bagalà C, Indellicati G, Zurlo V, Basso M, Cassano A, Larocca LM, Barone C.

Clin Transl Oncol. 2016 Oct;18(10):988-95. doi: 10.1007/s12094-015-1471-z. Epub 2016 Jan 7.


Preoperative chemoradiation, pancreaticoduodenectomy, and intraoperative radiation therapy for adenocarcinoma of the pancreatic head.

Staley CA, Lee JE, Cleary KR, Abbruzzese JL, Fenoglio CJ, Rich TA, Evans DB.

Am J Surg. 1996 Jan;171(1):118-24; discussion 124-5.


5-fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) as second-line chemotherapy in patients with metastatic pancreatic adenocarcinoma.

Assaf E, Verlinde-Carvalho M, Delbaldo C, Grenier J, Sellam Z, Pouessel D, Bouaita L, Baumgaertner I, Sobhani I, Tayar C, Paul M, Culine S.

Oncology. 2011;80(5-6):301-6. doi: 10.1159/000329803. Epub 2011 Jul 18.


Supplemental Content

Support Center